The original success of the copyright undeniably reshaped the medication landscape, but placing funds in companies heavily reliant on unbranded versions presents a uncertain picture. While early earnings were substantial, the cessation of patents and the rise of discounted alternatives have eroded sales. Consequently, a thorough assessment of prese